Abstract: Hydration mediums for hydrating hydrophilic coatings of urinary catheters and urinary catheter products containing such hydration mediums. Methods for making urinary catheter products having hydration mediums.

Abstract: A catheter drainage member (112) configured to be attached to a catheter tube (116), the drainage member comprising: body (115) having an inner surface (114); a well (120) defined by the inner surface of the body, the well configured to receive the catheter tube and an adhesive (122); and wherein the well is configured to selectively distribute the adhesive between the inner surface and the tube.

Abstract: Provided is a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as defined herein for use in the treatment or prevention of a Dirofilaria infection in a mammal, The compounds are also for use in the treatment or prevention of diseases or conditions caused by a Dirofilaria infection in a mammal. Also described are corresponding methods of treating or preventing a Dirofilaria infection in a mammal.

Abstract: The present invention relates to compounds of Formulae I and II as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae I and II, and to the use of compounds of Formulae I and II in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

Abstract: Catheters including an improved structure for effectively draining fluids from the urethra, that assist in reducing the likelihood of UTIs (Urinary Tract Infections) by flushing the urethra during catheterization.

Abstract: A urinary catheter is disclosed. The urinary catheter comprises a catheter tube having a proximal insertion end and a distal end. The catheter also comprises a drainage member. The drainage member includes a wall having an inner surface and an outer surface. The inner surface defines a drainage lumen having an opening in a proximal end of the drainage member. The distal end of the catheter tube is inserted through the opening of the proximal end of the drainage member and is located in the lumen. The wall of the drainage member has at least one window therethrough. The drainage member and the catheter tube are welded to one another at one or more welding sites in the vicinity of the window(s).

Abstract: An intermittent urinary catheter assembly 100 includes a reinforcement member 106 extending longitudinally at least partially within the distal end portion of the inner drainage lumen 104 of the catheter shaft. The reinforcement member may serve to connect a drainage member 114 to the catheter shaft and includes a drainage passageway in fluid communication with the inner drainage lumen of the shaft for allowing the drainage of urine through the urinary catheter assembly.

Abstract: Hydration mediums, assemblies containing hydration mediums and methods of making the same.

Abstract: The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

Abstract: Hydration mediums for hydrating hydrophilic coatings of urinary catheters and urinary catheter products containing such hydration mediums. Methods for making urinary catheter products having hydration mediums.

Abstract: A catheter drainage member (112) configured to be attached to a catheter tube (116), the drainage member comprising: body (115) having an inner surface (114); a well (120) defined by the inner surface of the body, the well configured to receive the catheter tube and an adhesive (122); and wherein the well is configured to selectively distribute the adhesive between the inner surface and the tube.

Abstract: Hydration mediums, assemblies containing hydration mediums and methods of making the same are disclosed. The hydration mediums are intended for hydrating or wetting a medical device such as a catheter and comprise a hydration foam. Furthermore, methods and products involving hydrophilic substances are disclosed e.g. involving mucilage, deep eutectic liquids, antifreeze substances or cryoprotectants, oil or a hydration medium together with water, surfactant, polyol and stabilizer.

Abstract: Hydration mediums, assemblies containing hydration mediums and methods of making the same are disclosed. The hydration mediums are intended for hydrating or wetting a medical device such as a catheter and comprise a hydration foam. Furthermore, methods and products involving hydrophilic substances are disclosed e.g. involving mucilage, deep eutectic liquids, antifreeze substances or cryoprotectants, oil or a hydration medium together with water, surfactant, polyol and stabilizer.

Abstract: The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.

Abstract: A drilling system for use at a wellhead has a plurality of modules each containing rig component equipment. The plurality of modules are connected or interconnected together so as to form a drilling rig. Each of the plurality of modules has a size adapted to be lifted by forklift or a front end loader. The plurality of modules are arranged such that one end of the plurality of modules is adjacent to the wellhead. A pipe handling system is positioned adjacent to one end of the plurality of modules. A ventilation system is cooperative with the plurality of modules so as to move air toward or away from heat-generating equipment in the plurality of modules.

Abstract: The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.

Abstract: The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.

Abstract: In embodiments of a flexible display extendable assembly, an extendable assembly includes a slideable display guide integrated in a first housing part of an extendable electronic device. The extendable electronic device includes a flexible display that slide-engages into the first housing part of the extendable electronic device. The extendable assembly includes an extendable mechanism that is coupled in a second housing part of the extendable electronic device and to the slideable display guide. The first and second housing parts of the extendable electronic device slide-engage relative to each other. The extendable mechanism is implemented to extend as the first and second housing parts slide apart relative to each other, and also to retract as the first and second housing parts slide together relative to each other.